VarmX

News & events

Enables initiation of global EquilibriX-S trial later this year Critical milestone in development of novel bypass agent to restore coagulation,...

Leiden, The Netherlands, 26 June 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...

Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.

...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...

VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking...

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will...